📊 Full opportunity report: One Index For GLP-1 Medication Stock, Doses, And Prices on IdeaNavigator AI — validation score, market gap, and execution plan.
Get business pricing on tech for your team
- Business-only prices and quantity discounts
- Tax-exempt purchasing
- Multiple users, one account, clear invoices
TL;DR
A market analysis from IdeaNavigator AI proposes a two-sided GLP-1 pharmacy index that would let consumers find which pharmacy has their dose in stock at the lowest cash price, while licensing the underlying data to telehealth, employer and PBM buyers. The proposal responds to fragmented pricing that ranges from roughly $199 to over $1,000 per month for the same drugs.
A GLP-1 pharmacy index — a single, normalized tracker of dose-level drug availability and cheapest legitimate cash prices for Ozempic, Wegovy, Zepbound and Mounjaro across US pharmacies — has been proposed by IdeaNavigator AI as a way to solve a problem that has shifted from national shortage to local fragmentation. The proposal, outlined in a market analysis, calls for a free consumer stock-and-price finder funded by licensing the underlying data feed to telehealth prescribers, employer benefits teams and PBMs.
The proposal targets a gap that has emerged since the FDA declared GLP-1 shortages resolved — tirzepatide in December 2024 and semaglutide in February 2025, according to the analysis. Even with the national shortages over, patients still encounter localized stockouts of specific doses and cash prices that the analysis says swing from roughly $199 to more than $1,000 per month depending on whether the purchase is made through LillyDirect, NovoCare, Costco, Walmart or a retail pharmacy.
The proposed product would work in two layers. A free consumer-facing web tool would let patients search by drug, dose and ZIP code to find nearby stock and the cheapest legitimate cash price, seeded with crowdsourced stock reports and normalized public pricing data from manufacturer direct sites, Costco and Walmart cash programs, and a GoodRx-style price layer. On top of that, dose-level availability alerts would notify patients when a specific strength returns to stock.
The commercial layer would expose the normalized availability and price dataset as a B2B API and dashboard licensed to telehealth prescribers, employer benefits teams, and pharmacy benefit managers or brokers. Revenue would come from these data licenses and possible referral fees to legitimate pharmacy or manufacturer-direct channels, according to the proposal. The analysis emphasizes that the index would cover brand-name GLP-1s only and would not act as a clinical affiliate of any drug.
Why Price Fragmentation Now Hurts Patients and Employers
The proposal matters because the GLP-1 market has moved from a supply crisis to a fragmentation problem. With brand drugs off the FDA shortage list and compounding deadlines forcing compounders out, manufacturers simultaneously launched competing direct cash-pay channels — LillyDirect, NovoCare, and Costco and Walmart programs, plus the TrumpRx portal in February 2026 as cited in the analysis. The result is a sprawl of prices and dose-level supply gaps that no single neutral source normalizes.
For employers, the stakes are financial. The analysis states that employers report GLP-1s now account for roughly 20% of pharmacy spend, creating demand for cost-steering data that a normalized feed could supply. For patients, the practical benefit is avoiding the common experience of arriving at a pharmacy only to find their specific dose is out of stock, or overpaying by hundreds of dollars per month by missing a cheaper legitimate channel. The absence of any machine-readable, dose-level index, the analysis argues, is the core unmet need.
Top picks for "index medication stock"
As an affiliate, we earn on qualifying purchases.
How the GLP-1 Channel Landscape Got This Splintered
Through 2022 to 2024, the dominant GLP-1 story was shortage: soaring demand for Ozempic, Wegovy, Zepbound and Mounjaro outstripped manufacturing capacity, and the FDA’s shortage listings opened the door for compounders to sell copied versions. That era closed in stages — the FDA removed tirzepatide from the shortage list in December 2024 and semaglutide in February 2025, and enforcement deadlines pushed compounders out of the copied-drug market.
What replaced the shortage was a set of parallel, non-interoperable cash-pay channels. Eli Lilly’s LillyDirect and Novo Nordisk’s NovoCare both sell direct to patients at self-pay prices, Costco and Walmart run their own cash programs, and the TrumpRx portal entered the field in February 2026, according to the analysis. Each channel prices independently, and each pharmacy location manages its own dose-level inventory, which is why the same drug and dose can carry sharply different prices and availability within a single metro area.
What the GLP-1 Index Proposal Has Not Yet Proven
The index described here is a proposal, not a launched product. No consumer tool, B2B API or licensed feed exists yet, and the figures cited — including the $199-to-$1,000+ price range and the 20% employer pharmacy-spend share — are presented in the analysis without an independent third-party audit or published dataset behind them.
Several practical questions remain open. It is not yet clear whether crowdsourced stock reports can achieve enough density and accuracy to be useful at dose level, whether manufacturer direct channels will permit normalized scraping of their prices, or how quickly price data would go stale. The analysis also does not specify how patient-submitted reports would be verified or moderated, and it does not name any telehealth, employer or PBM that has expressed interest — design partners are described only as targets.
The 60-Day Test for Stock Reports and Pilot Deals
The proposal sets out a concrete validation plan. Within 60 days, the plan calls for building a single-metro crowdsourced stock and cash-price tracker covering the four brand GLP-1s, paired with paid landing-page tests aimed at two buyer segments: a consumer page pitched as a ‘find my dose cheapest near me’ tool, and a B2B page pitching the normalized availability and price API to telehealth and employer-benefits teams.
The analysis defines success thresholds: at least 200 consumer stock reports submitted in one metro, and at least two B2B prospects signing a paid pilot or letter of intent for the feed. If those thresholds are met, the next step would be expanding from one metro to broader coverage and layering on dose-level availability alerts. If they are not, the analysis treats that as a signal to stop before building the full two-sided platform.
Source: IdeaNavigator AI
Key Questions
Is the GLP-1 pharmacy index available to use today?
No. It exists only as a proposal with a 60-day validation plan. No consumer finder, B2B API or dashboard has been built or launched yet.
Which medications would the index cover?
The proposal covers the four brand-name GLP-1s: Ozempic, Wegovy, Zepbound and Mounjaro — tracked by drug, dose and ZIP code. Compounded versions are outside its scope.
Why do GLP-1 cash prices vary so much between pharmacies?
Manufacturer direct channels like LillyDirect and NovoCare, retailer cash programs at Costco and Walmart, and traditional pharmacies each set prices independently. The analysis says this produces a spread from roughly $199 to over $1,000 per month for the same medications.
How would the index make money if the consumer tool is free?
Revenue would come from licensing the normalized availability and price feed to telehealth prescribers, employer benefits teams and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels.
What has to happen for the proposal to move forward?
Per the validation plan, at least 200 crowdsourced consumer stock reports must be submitted in a single metro and at least two B2B prospects must sign a paid pilot or letter of intent within 60 days.
Source: IdeaNavigator AI
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
